Clinical Trial Update: A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer [Phase 2, Phase 3]

View source ↗

Summary

A study of HS-20117 in combination with Aumolertinib is being conducted for advanced non-squamous non-small cell lung cancer in Phase 2/3, and is currently recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Aumolertinib (Aumolertinib)
• HS-20117

Snippet

Sponsor: Hansoh BioMedical R&D Company | Conditions: Non-Squamous Non-Small Cell Lung Cancer | Phase 2, Phase 3 | Status: RECRUITING